{"classes":[{"categories":[{"measurements":[{"comment":"Since only a few patients died, the median survival was not estimable by Kaplan-Meier method nor the 90% confidence interval.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Defined as the time from start of induction treatment to 3 years post first study treatment or death from any cause, whichever comes first. Patient must have completed at least 1 cycle to be included in analysis.","dispersionType":"90% Confidence Interval","groups":[{"description":"INDUCTION:\n\nCycles 1-2: elotuzumab 10mg/kg IV days 1, 8, 15, 22; lenalidomide (len) 25mg orally (PO), once daily (QD) on days 1-21; dexamethasone (dex) 28 mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1, 8, 15, 22.\n\nCycles 3-4: elotuzumab 10mg/kg IV days 1 and 15; len 25mg PO QD days 1-21; dex 8mg PO (3-24 hrs before elotuzumab IV) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.\n\nCONSOLIDATION:\n\nFour 28-day cycles: elotuzumab 10mg/kg IV days 1 and 15; len 15mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes before elotuzumab) days 1 and 15; dex 40mg PO days 8 and 22.\n\nMAINTENANCE:\n\nAfter completing consolidation therapy patients without progressive disease will receive, for up to 24 months, 28-day cycles of elotuzumab 20mg/kg IV day 1; len 10mg +/- 5mg PO QD days 1-21; dex 28mg PO (3-24 hrs before elotuzumab) and 8mg IV (45-90 minutes prior to elotuzumab) day 1.\n\nelotuzumab: Given intravenously (IV)\n\nLenalidomide: Given by IV\n\nDexamethasone: Given orally (PO) or by IV\n\nautologous stem cell transplantation","id":"OG000","title":"ERd Therapy"}],"paramType":"MEDIAN","populationDescription":"Participants who completed at least one cycle of treatment were included in the analysis. One participant didn't complete cycle 1 due to adverse events; therefore, excluded from the analysis.","reportingStatus":"POSTED","timeFrame":"every 4 weeks until end of treatment visit, and up to 3 years thereafter","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}